Pancreatic Cancer in the General Population: Improvements in Survival Over the Last Decade

Journal of Gastrointestinal Surgery

Volumn 10, Issue 9, 2006, Pages 1212-1224

  Riall, Taylor S ^a   Nealon, William H ^a   Goodwin, James S ^a   Zhang, Dong ^a   Kuo, Yong Fang ^a   Townsend Jr , Courtney M ^a   Freeman, Jean L ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

pancreatic cancer; SEER; survival

Indexed keywords

ARTICLE; CANCER REGISTRY; FEMALE; HUMAN; MALE; MORTALITY; PANCREAS TUMOR; SURVIVAL RATE; UNITED STATES;

FEMALE; HUMANS; MALE; PANCREATIC NEOPLASMS; SEER PROGRAM; SURVIVAL RATE; UNITED STATES;

EID: 33751006429     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gassur.2006.08.010     Document Type: Article

References (39)

1. U.S. Cancer Statistics Working Group. United States Cancer Statistics: 2002 Incidence and Mortality (2005), U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute, Atlanta
2. Yeo T.P., Hruban R.H., Leach S.D., et al. Pancreatic cancer. Curr Prob Cancer 26 (2002) 176-275
3. Crile Jr. G. The advantages of bypass over radical pancreaticoduodenectomy in the treatment of pancreatic carcinoma. Surg Gynecol Obstet 130 (1970) 1049-1053
4. Shapiro T.M. Adenocarcinoma of the pancreas: A statistical analysis of bypass vs. Whipple resection in good risk patients. Ann Surg 182 (1975) 715-721
5. Sohn T.A., Yeo C.J., Lillemoe K.D., et al. Resected adenocarcinoma of the pancreas - 616 patients: Results, outcomes, and prognostic indicators. J Gastrointest Surg 4 (2000) 567-579
6. Geer R.J., and Brennan M.F. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg 217 (1993) 43-49
7. Trede M., Schwall G., and Saeger H.-D. Survival after pancreaticoduodenectomy:118 consecutive resections without a mortality. Ann Surg 211 (1990) 447-458
8. Cameron J.L., Pitt H.A., Yeo C.J., et al. One hundred and forty five consecutive pancreaticoduodenectomies without mortality. Ann Surg 217 (1993) 430-438
9. Yeo C.J., Cameron J.L., Sohn T.A., et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: Pathology, complications, outcomes. Ann Surg 226 (1997) 248-260
10. Riall T.S., Cameron J.L., Lillemoe K.D., et al. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma-Part 3: Update on 5-year survival. J Gastrointest Surg 9 (2005) 1191-1206
11. Balcom J.H., Rattner D.W., Warshaw A.L., et al. Ten-year experience with 733 pancreatic resections: Changing indications, older patients, and decreasing length of hospitalization. Arch Surg 136 (2001) 391-398
12. Coquard R., Ayzac L., Romestaing P., et al. Adenocarcinoma of the body and tail of the pancreas: Is there room for adjuvant radiotherapy?. Tumori 83 (1997) 740-742
13. Dalton R.R., Sarr M.G., van Heerden J.A., et al. Carcinoma of the body and tail of the pancreas: Is curative resection justified?. Surgery 111 (1992) 489-494
14. Brennan M.F., Moccia R.D., and Klimstra D. Management of adenocarcinoma of the body and tail of the pancreas. Ann Surg 223 (1996) 506-512
15. Yeo C.J., Sohn T.A., Cameron J.L., et al. Periampullary adenocarcinoma: Analysis of 5-year survivors. Ann Surg 227 (1998) 821-831
16. Riall TS, Cameron JL, Lillemoe KD, et al. Resected periampullary adenocarcinoma: 5-year survivors and their 6- to 10- year follow-up. Surgery (in press).
17. Sosa J.A., Bowman H.M., Gordon T.A., et al. Importance of hospital volume in the overall management of pancreatic cancer. Ann Surg 228 (1998) 429-438
18. Gordon T.A., Burleyson G.P., Tielsch J.M., et al. The effects of regionalization on cost and outcome for one general high-risk surgical procedure. Ann Surg 221 (1995) 43-49
19. Birkmeyer J.D., Finlayson S.R., Tosteson A.N., et al. Effect of hospital volume on in-hospital mortality with pancreaticoduodenectomy. Surgery 125 (1999) 250-256
20. Gouma D.J., van Geenen R.C., van Gulik T.M., et al. Rates of complications and death after pancreaticoduodenectomy: Risk factors and the impact of hospital volume. Ann Surg 232 (2000) 786-795
21. Rosemurgy A.S., Bloomston M., Serafini F.M., et al. Frequency with which surgeons undertake pancreaticoduodenectomy determines length of stay, hospital charges, and in-hospital mortality. J Gastrointest Surg 5 (2001) 21-26
22. Ho V., and Heslin M.J. Effect of hospital volume and experience on in-hospital mortality for pancreaticoduodenectomy. Ann Surg 237 (2003) 509-514
23. Cress R.D., Yin D., Clarke L., et al. Survival among patients with adenocarcinoma of the pancreas: A population-based study. Cancer Causes Control 17 (2006) 403-409
24. National Cancer Institute. Surveillance, Epidemiology, and End Results Program (SEER). Available at: http//:www.seer.cancer.gov. Accessed May 1, 2006.
25. Kaplan E., and Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
26. Cox D.R. Regression models and life tables. J R Stat Soc 34 (1972) 187-220
27. Conlon K.C., Klimstra D.S., and Brennan M.F. Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Ann Surg 223 (1996) 273-279
28. Glimelius B., Hoffman K., Sjoden P.O., et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 7 (1996) 593-600
29. Cunningham D., Chau I., Stocken D., et al. Phase III randomised comparison of gemcitabine (GEM) versus gemcitabine plus cpecitabine (GEM-CAP) in patients with advanced pancreatic cancer. Eur J Cancer Suppl (2005) 4, abstr PS11
30. Cascinu S, Frontini L, Labianca R, et al. A combination of a fixed dose rate infusion of Gemcitabine associated to a bolus 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Ann Oncol;11:1309-1311.
31. Berlin J.D., Adak S., Vaughn D.J., et al. A phase II study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic adenocarcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncology 20 (2002) 3270-3275
32. Di Constanzo F., Carlini P., Doni L., et al. Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: A randomised phase II trial of the Italian Oncology Group for clinical research (GOIRC). Br J Cancer 93 (2005) 185-189
33. Smeenk H.G., de Castro S.M., Jeekel J.J., et al. Locally advanced pancreatic cancer treated with radiation and 5-flourouracil: A first step to neoadjuvant treatment?. Dig Surg 22 (2005) 191-197
34. Yeo C.J., Abrams R.A., Grochow L.B., et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: Postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg 225 (1997) 621-633
35. Jacobs A.D., Otero H., Picozzi V.J., et al. Gemcitabine combined with docetaxel for the treatment of unresectable pancreatic carcinoma. Cancer Invest 22 (2004) 505-514
36. Shoup M., Conlon K.C., Klimstra D.S., et al. Is extended resection for adenocarcinoma of the body or tail of the pancreas justified?. J Gastrointest Surg 7 (2003) 946-952
37. Ridewlski K., Meyer F., Schmidt U., et al. Results of surgical treatment in ampullary and pancreatic carcinoma and its prognostic parameters after R0-resection. Zentralbl Chir 130 (2005) 353-361
38. Krzyzanowska M.K., Weeks J.C., and Earle C.C. Treatment of locally advanced pancreatic cancer in the real world: Population-based practices and effectiveness. J Clin Oncol 21 (2003) 3409-3414
39. Feinstein A.R., Sosin D.M., and Wells C.K. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 312 (1985) 1604-1608